"Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof."
ALBUQUERQUE, N.M.--Senior Scientific, LLC, a unit of Manhattan Scientifics (MHTX: OTCQB) and a developer of nanobiotechnology for the early detection and localization of cancer and other human diseases, today announced that the Company has recently been granted a patent by the Chinese Patent Office, Patent No. CN102695473 A, covering the "Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof." This patent is an additional patent granted for its MRX™ cancer detection technology that has been granted and issued in by the U.S. Patent office under U.S. Patent No. US 9,095,270 B2.
Bob Proulx, COO and President of Senior Scientific said, “This patent significantly strengthens our IP portfolio for our core MRX technology. With our proprietary cancer detection technology now protected in both the U.S. and China, the two largest markets by population, we now have leverage to pursue a global commercialization and licensing strategy.”
Manhattan Scientifics Inc. (www.mhtx.com) is focused on commercialization of disruptive technologies in the nano medicine space.
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.